Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
Loading...
Embargo End Date
ICR Authors
Authors
Napolitano, A
Ostler, AE
Jones, RL
Huang, PH
Ostler, AE
Jones, RL
Huang, PH
Document Type
Journal Article
Date
2021-06-17
Date Accepted
2021-06-15
Abstract
Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling pathway have been identified in a range of different sarcoma subtypes, most notably gastrointestinal stromal tumors, rhabdomyosarcomas, and liposarcomas. These alterations include genetic events such as translocations, mutations, and amplifications as well as transcriptional overexpression. Targeting FGFR has therefore been proposed as a novel potential therapeutic approach, also in light of the clinical activity shown by multi-target tyrosine kinase inhibitors in specific subtypes of sarcomas. Despite promising preclinical evidence, thus far, clinical trials have enrolled very few sarcoma patients and the efficacy of selective FGFR inhibitors appears relatively low. Here, we review the known alterations of the FGFR pathway in sarcoma patients as well as the preclinical and clinical evidence for the use of FGFR inhibitors in these diseases. Finally, we discuss the possible reasons behind the current clinical data and highlight the need for biomarker stratification to select patients more likely to benefit from FGFR targeted therapies.
Citation
Cells, 10 (6), pp. 1533 - 1533
Source Title
Publisher
MDPI
ISSN
eISSN
2073-4409
Collections
Research Team
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology
Molecular and Systems Oncology
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology